Look up one drug

Ontario coverage, price, criteria word for word, Health Canada status and shortages for one product

Patient plan: look up a medication list

APREPITANT

All products: Limited Use (codes 452, 453)

Other products in the same Health Canada class (A04A, A04AD) — coverage varies; not interchangeable

  • Nabilone (Cesamet): general benefit, Not a benefit
  • Granisetron (Kytril): limited Use 326, 454, Not a benefit
  • Netupitant + palonosetron (Akynzeo): limited Use 561, 562
  • Ondansetron (Zofran ODT (Tablet)): limited Use 215, 216, 217, 218, 454, 696, Not a benefit
  • Ondansetron (Zofran): not a benefit

Emend Tri-Pack · DIN 02298813 · 125mg & 80mg · capsule

Limited Use — Reason for Use code 452, 453 requiredMarketed · checked 2026-09-02
StatusLimited Use — Reason for Use code 452, 453 required
Write on scriptLU code 452, 453 (patient must meet the criteria below)
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.

Ministry criteria list dated January 1, 2025; the program's current criteria may differ; SADIE shows the current version. Current criteria in SADIE

Ontario Limited Use criteria — code 452, 453
Reason for Use code 452 In combination with a 5HT3 receptor antagonist and dexamethasone for highly emetogenic chemotherapy (HEC) regimens: - Cisplatin-based chemotherapy where a single daily dose is greater than or equal to 70 mg per meter squared - Cisplatin and cyclophosphamide combinations where the single daily dose is greater than or equal to 50mg per meter squared - Cisplatin (any dose) given for 3 to 5 consecutive days - Non-cisplatin based highly emetogenic chemotherapy (such as those containing anthracycline greater than or equal to 60mg per meter squared plus cyclophosphamide) Dosage: Recommend aprepitant 125mg orally on Day 1 of HEC followed by 80mg orally on Days 2 to 3 post-chemotherapy for each cycle. Coverage limit: LU Authorization Period: 1 year Reason for Use code 453 For patients receiving moderately emetogenic chemotherapy (MEC) regimens AND who have had inadequate symptom control using a 5HT3 antagonist and dexamethasone in a previous cycle. Dosage: Recommend aprepitant 125mg orally on Day 1 of MEC followed by 80mg orally on Days 2 to 3 post-chemotherapy for each cycle. Coverage limit: LU Authorization Period: 1 year Exceptional Access criteria on record are for Brand(s): Emend; DOSAGE FORM/ STRENGTH: 80 mg,125 mg capsule,Tri-pack — not this product; no criteria on record for this product in this block. Exceptional Access Program criteria on record (ministry list dated 2025-01-01, not exhaustive): Ministry criteria list dated January 1, 2025; the program's current criteria may differ; SADIE shows the current version. https://www.ontario.ca/page/sadie-special-authorization-digital-information-exchange Aprepitant Brand(s): Emend DOSAGE FORM/ STRENGTH: 80 mg,125 mg capsule,Tri-pack Effective September 25, 2014, Emend transitioned to the ODB formulary for reimbursement in patients who meet the Limited Use criteria. Dosage regimens not meeting the LU criteria may be submitted to the EAP for consideration of reimbursement. EAP source: eap-frequently-requested-drugs-2025-01-01.txt, page 392, record 224, corpus 2025-01-01; name match only, not an eligibility decision
No interchangeable product listed in the Ontario extract
Emend Tri-Pack · DIN 02298813 Manufacturer: Merck Canada Inc.; listing date 2014-09-25 Health Canada: Marketed since 2007-09-24 · brand EMEND TRI-PACK · ATC A04AD12 APREPITANT · form Capsule, Kit · route Oral · ingredients APREPITANT 80 MG, APREPITANT 125 MG · company Merck canada inc · schedule Prescription
Check this DIN again · Health Canada product record

Emend Tri-Pack: Formulary list price $106.9839/unit (unit not stated in source; not the patient's cost)

Ministry pays: $106.9839 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=78412 · Verify on the e-Formulary ↗ (DIN 02298813)

Source record
DIN 02298813: Emend Tri-Pack Raw flags: sec12=Y, sec3=Y Item: 562200043; group id 662; item number 1650; lccId 00243; manufacturer id MEK Source form: Cap; strength: 125mg & 80mg Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below Source prices (unrounded): $106.9839; ministry $106.9839 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02298813 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=78412
Shortage status: To be discontinued · Tier 3; reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02298813
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Other drugs in the same formulary class (56:22 Antiemetics and Antinauseants) and how they are covered

Matched class: 56:22 Antiemetics and Antinauseants

Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment. Covered without a code on the Ontario formulary: DOXYLAMINE SUCCINATE AND PYRIDOXINE HCL, MECLIZINE HCL Some products covered without a code (check the product listing): NABILONE 56:22 Antiemetics and Antinauseants

NABILONE

· 10 products · Off-Formulary Interchangeable, not an ODB benefit (4), General benefit (6) · strengths: 0.25mg, 0.5mg, 1mg · Cap

GRANISETRON HCL

· 4 products · Listed, not a benefit (1), Limited Use, codes 91, 92, 93, 326, 454 (3) · strengths: 1mg · Tab

NETUPITANT & PALONOSETRON HYDROCHLORIDE

· 1 products · Limited Use, codes 561, 562 · strengths: 300mg & 0.5mg · Cap

ONDANSETRON HYDROCHLORIDE

· 54 products · Listed, not a benefit (5), Limited Use, codes 215, 216, 217, 218, 454, 696 (49) · strengths: 4mg, 8mg, 4mg/5mL · O/L, Tab

ONDANSETRON HCL DIHYDRATE

· 6 products · Off-Formulary Interchangeable, not an ODB benefit · strengths: 2mg/mL · Inj Sol-2mL Pk, Inj Sol-4mL Pk

DOXYLAMINE SUCCINATE AND PYRIDOXINE HCL

· 4 products · General benefit · strengths: 10mg & 10mg · SR Tab

MECLIZINE HCL

· 1 products · General benefit · strengths: 25mg · Tab

DIMENHYDRINATE

· 2 products · Limited Use, codes 481 · strengths: 50mg/mL · Inj Sol (with Preservative) Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26; class 56:22
Full class listing Related classes: 56:04 Antacids and Adsorbents, 56:08 Antidiarrhea Agents, 56:12 Cathartics, 56:16 Digestants, 56:40 Miscellaneous G.I. Drugs Same formulary class, not same indication: class membership alone does not establish equivalent uses.
What the Health Canada label says it is for
INDICATIONS AND CLINICAL USE EMEND® (aprepitant), in combination with a 5-HT3 antagonist class of antiemetics and dexamethasone, is indicated for the: 1. prevention of acute and delayed nausea and vomiting due to highly emetogenic cancer chemotherapy https://pdf.hres.ca/dpd_pm/00023565.PDF PM date: not printed or not captured Source product: EMEND TRI-PACK; DIN 02298813; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.

Availability

Emend Tri-Pack · DIN 02298813 Shortage status: To be discontinued · Tier 3; reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02298813

Check this DIN again

Prepare an Exceptional Access request

SADIE has its own form for many drugs; this checklist prepares the answers; the ministry decides. Open SADIE

Use this text in SADIE’s free-text fields or read from it on a Telephone Request Service call. Review marks do not indicate eligibility. Evidence stays in this page until you copy it; nothing entered here is sent or saved. Do not enter patient identifiers.

EAP Telephone Request Service: The TRS can be accessed by calling toll-free at 1-866-811-9893 or 416-327-8109 (Toronto area) between 8:30 a.m. and 5:00 p.m. Monday through Friday (except holidays) and selecting the TRS option. Source; updated September 15, 2026

EAP fax: In Ontario: 1-866-811-9908 or 416-327-7526 (Toronto area). Outside Ontario: 1-833-905-4260. Source; updated September 15, 2026

Posted turnaround and Telephone Request Service scope
Turnaround times The Exceptional Access Program receives between 250 and 500 requests a day. Requests are categorized in order of priority based on how quickly a drug is needed, the type of drug, and the condition for which the drug is being used. Turnaround times begin on the business day on which the EAP receives a complete request from a physician or nurse practitioner. You may have to wait longer if the request is missing information or supporting documents required by the EAP criteria, if a request requires external review, or if documents are sent by fax or mail instead of submitted via SADIE. EAP Weekly Progress Report Date: September 15, 2026 Processing categories and examples | Target | Current | Priority 1 — for drugs such as antibiotics, cancer medications, and initial requests for pain medications | 3 business days | 2 business day | Priority 2 — for antiviral drugs to treat HIV, drugs for multiple sclerosis, and pulmonary hypertension | 5 business days | 3 business days | Biologics — for biologic drugs to treat rheumatoid arthritis, psoriatic arthritis, ulcerative colitis and Crohn’s disease | 10 business days | 4 business days | Chronic — for drugs used for chronic conditions such as migraines, chronic pain, Ménière's disease and symptoms of Parkinson’s disease. | 4 to 6 weeks | 11 business days |
For selected drugs, the Telephone Request Service is available to authorized prescribers or their delegates. In most cases, the funding decision is provided by the end of the call and processed within one business day.
Source; updated September 15, 2026

Aprepitant (Emend)

Ministry criteria list dated January 1, 2025; the program's current criteria may differ; SADIE shows the current version. Current criteria in SADIE

Prepare answers: See the ministry wording below; no separate indication heading is held.

Ministry criteria corpus 2025-01-01; page 392

Aprepitant Brand(s): Emend DOSAGE FORM/ STRENGTH: 80 mg,125 mg capsule,Tri-pack
Effective September 25, 2014, Emend transitioned to the ODB formulary for reimbursement in patients who meet the Limited Use criteria. Dosage regimens not meeting the LU criteria may be submitted to the EAP for consideration of reimbursement.

Prepared from the ministry's published criteria; eligibility is decided by the Exceptional Access Program.